Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin

Chia Jung Hsieh, Tae Woo Kim, Chien Fu Hung, Jeremy Juang, Michelle Moniz, David A K Boyd, Liangmei He, Pei Jer Chen, Chien Hung Chen, T. C. Wu

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Vaccinia vaccines have become important vectors for antigen-specific immunotherapy. Calreticulin has been shown to enhance MHC class I presentation of linked peptide/protein and may be useful for antigen-specific cancer treatment. An innovative vaccine administering antigen linked to calreticulin via a vaccinia vector may generate a potent antigen-specific antitumor response. We tested the efficacy of linking calreticulin (CRT) to model antigen human papilloma virus type 16 (HPV-16) E7 in the context of a vaccinia vaccine (Vac-CRT/E7). Intraperitoneal vaccination of C57BL/6 mice with Vac-CRT/E7 led to a dramatic increase in E7-specific IFN-γ-secreting CD8+ T cells and a potent antitumor effect against E7-expressing tumors compared to immunization with Vac-E7 or Vac-CRT. When compared to other chimeric vaccinia vaccines employing various intracellular targeting strategies previously developed in our lab, Vac-CRT/E7 elicited the highest number of E7-specific CD8+ T cells. Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy.

Original languageEnglish
Pages (from-to)3993-4001
Number of pages9
JournalVaccine
Volume22
Issue number29-30
DOIs
Publication statusPublished - 2004 Sep 28
Externally publishedYes

Fingerprint

Vaccine Potency
calreticulin
Calreticulin
Vaccinia
Vaccinium
Neoplasm Antigens
linkage (genetics)
vaccines
antigens
neoplasms
Genes
Antigens
Vaccines
genes
immunotherapy
Papillomaviridae
Immunotherapy
Vaccination
T-lymphocytes
vaccination

Keywords

  • Calreticulin
  • Cancer immunotherapy
  • Vaccinia vaccines

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Hsieh, C. J., Kim, T. W., Hung, C. F., Juang, J., Moniz, M., Boyd, D. A. K., ... Wu, T. C. (2004). Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine, 22(29-30), 3993-4001. https://doi.org/10.1016/j.vaccine.2004.03.057

Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. / Hsieh, Chia Jung; Kim, Tae Woo; Hung, Chien Fu; Juang, Jeremy; Moniz, Michelle; Boyd, David A K; He, Liangmei; Chen, Pei Jer; Chen, Chien Hung; Wu, T. C.

In: Vaccine, Vol. 22, No. 29-30, 28.09.2004, p. 3993-4001.

Research output: Contribution to journalArticle

Hsieh, CJ, Kim, TW, Hung, CF, Juang, J, Moniz, M, Boyd, DAK, He, L, Chen, PJ, Chen, CH & Wu, TC 2004, 'Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin', Vaccine, vol. 22, no. 29-30, pp. 3993-4001. https://doi.org/10.1016/j.vaccine.2004.03.057
Hsieh, Chia Jung ; Kim, Tae Woo ; Hung, Chien Fu ; Juang, Jeremy ; Moniz, Michelle ; Boyd, David A K ; He, Liangmei ; Chen, Pei Jer ; Chen, Chien Hung ; Wu, T. C. / Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. In: Vaccine. 2004 ; Vol. 22, No. 29-30. pp. 3993-4001.
@article{e1347f71de244102b050dbb4d7cb49d0,
title = "Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin",
abstract = "Vaccinia vaccines have become important vectors for antigen-specific immunotherapy. Calreticulin has been shown to enhance MHC class I presentation of linked peptide/protein and may be useful for antigen-specific cancer treatment. An innovative vaccine administering antigen linked to calreticulin via a vaccinia vector may generate a potent antigen-specific antitumor response. We tested the efficacy of linking calreticulin (CRT) to model antigen human papilloma virus type 16 (HPV-16) E7 in the context of a vaccinia vaccine (Vac-CRT/E7). Intraperitoneal vaccination of C57BL/6 mice with Vac-CRT/E7 led to a dramatic increase in E7-specific IFN-γ-secreting CD8+ T cells and a potent antitumor effect against E7-expressing tumors compared to immunization with Vac-E7 or Vac-CRT. When compared to other chimeric vaccinia vaccines employing various intracellular targeting strategies previously developed in our lab, Vac-CRT/E7 elicited the highest number of E7-specific CD8+ T cells. Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy.",
keywords = "Calreticulin, Cancer immunotherapy, Vaccinia vaccines",
author = "Hsieh, {Chia Jung} and Kim, {Tae Woo} and Hung, {Chien Fu} and Jeremy Juang and Michelle Moniz and Boyd, {David A K} and Liangmei He and Chen, {Pei Jer} and Chen, {Chien Hung} and Wu, {T. C.}",
year = "2004",
month = "9",
day = "28",
doi = "10.1016/j.vaccine.2004.03.057",
language = "English",
volume = "22",
pages = "3993--4001",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "29-30",

}

TY - JOUR

T1 - Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin

AU - Hsieh, Chia Jung

AU - Kim, Tae Woo

AU - Hung, Chien Fu

AU - Juang, Jeremy

AU - Moniz, Michelle

AU - Boyd, David A K

AU - He, Liangmei

AU - Chen, Pei Jer

AU - Chen, Chien Hung

AU - Wu, T. C.

PY - 2004/9/28

Y1 - 2004/9/28

N2 - Vaccinia vaccines have become important vectors for antigen-specific immunotherapy. Calreticulin has been shown to enhance MHC class I presentation of linked peptide/protein and may be useful for antigen-specific cancer treatment. An innovative vaccine administering antigen linked to calreticulin via a vaccinia vector may generate a potent antigen-specific antitumor response. We tested the efficacy of linking calreticulin (CRT) to model antigen human papilloma virus type 16 (HPV-16) E7 in the context of a vaccinia vaccine (Vac-CRT/E7). Intraperitoneal vaccination of C57BL/6 mice with Vac-CRT/E7 led to a dramatic increase in E7-specific IFN-γ-secreting CD8+ T cells and a potent antitumor effect against E7-expressing tumors compared to immunization with Vac-E7 or Vac-CRT. When compared to other chimeric vaccinia vaccines employing various intracellular targeting strategies previously developed in our lab, Vac-CRT/E7 elicited the highest number of E7-specific CD8+ T cells. Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy.

AB - Vaccinia vaccines have become important vectors for antigen-specific immunotherapy. Calreticulin has been shown to enhance MHC class I presentation of linked peptide/protein and may be useful for antigen-specific cancer treatment. An innovative vaccine administering antigen linked to calreticulin via a vaccinia vector may generate a potent antigen-specific antitumor response. We tested the efficacy of linking calreticulin (CRT) to model antigen human papilloma virus type 16 (HPV-16) E7 in the context of a vaccinia vaccine (Vac-CRT/E7). Intraperitoneal vaccination of C57BL/6 mice with Vac-CRT/E7 led to a dramatic increase in E7-specific IFN-γ-secreting CD8+ T cells and a potent antitumor effect against E7-expressing tumors compared to immunization with Vac-E7 or Vac-CRT. When compared to other chimeric vaccinia vaccines employing various intracellular targeting strategies previously developed in our lab, Vac-CRT/E7 elicited the highest number of E7-specific CD8+ T cells. Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy.

KW - Calreticulin

KW - Cancer immunotherapy

KW - Vaccinia vaccines

UR - http://www.scopus.com/inward/record.url?scp=84984552535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984552535&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2004.03.057

DO - 10.1016/j.vaccine.2004.03.057

M3 - Article

C2 - 15364449

AN - SCOPUS:84984552535

VL - 22

SP - 3993

EP - 4001

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 29-30

ER -